Exploiting machine learning for predicting skeletal-related events in cancer patients with bone metastases

The aim of the bone metastases (BM) treatment is to prevent the occurrence of skeletal-related events (SREs). In clinical, physicians could only predict the occurrence of SREs by subjective experience. Machine learning (ML) could be used as predictive models in the medical field. But there is no published research using ML to predict SREs in cancer patients with BM. The purpose of this study was to assess the associations of clinical variables with the occurrence of SREs and to subsequently develop prediction models to help identify SREs risk groups. We analyzed 1143 cancer patients with BM. We used the statistical package of SPSS and SPSS Modeler for data analysis and the development of the prediction model. We compared the performance of logistic regression (LR), decision tree (DT) and support vector machine(SVM). The results suggested that Visual Analog Scale (VAS) scale was a key factor to SREs in LR, DT and SVM model. Modifiable factors such as Frankel classification, Mirels score, Ca, aminoterminal propeptide of type I collagen (PINP) and bone-specific alkaline phosphatase (BALP) were identified. We found that the result of applying LR, DT and SVM classification accuracy was 79.2%, 85.8% and 88.2%, with 9, 4 and 8 variables, respectively. In conclusion, DT and SVM achieved higher accuracies with smaller number of variables than the number of variables used in LR. ML techniques can be used to build model to predict SREs in cancer patients with BM.

[1]  H. Kim,et al.  Prediction Model for Health-Related Quality of Life of Elderly with Chronic Diseases using Machine Learning Techniques , 2014, Healthcare informatics research.

[2]  Bo-Yeong Kang,et al.  Predictors of Medication Adherence in Elderly Patients with Chronic Diseases Using Support Vector Machine Models , 2013, Healthcare informatics research.

[3]  Bahram Goliaei,et al.  Prediction of lung tumor types based on protein attributes by machine learning algorithms , 2013, SpringerPlus.

[4]  Henrik Toft Sørensen,et al.  Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). , 2010, The Journal of urology.

[5]  Leo Breiman,et al.  Statistical Modeling: The Two Cultures (with comments and a rejoinder by the author) , 2001, Statistical Science.

[6]  J A Swets,et al.  Measuring the accuracy of diagnostic systems. , 1988, Science.

[7]  Leo Breiman,et al.  Statistical Modeling: The Two Cultures (with comments and a rejoinder by the author) , 2001 .

[8]  E F Cook,et al.  Asymmetric stratification. An outline for an efficient method for controlling confounding in cohort studies. , 1988, American journal of epidemiology.

[9]  Ivana Đurđević,et al.  Classification of entrepreneurial intentions by neural networks, decision trees and support vector machines , 2010 .

[10]  Zhi-yu Wang,et al.  CT fluoroscopy-guided percutaneous osteoplasty for the treatment of osteolytic lung cancer bone metastases to the spine and pelvis. , 2012, Journal of vascular and interventional radiology : JVIR.

[11]  M. Soloway,et al.  Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan , 1988, Cancer.

[12]  Zhi-yu Wang,et al.  Systematic literature review and network meta-analysis comparing bone-targeted agents for the prevention of skeletal-related events in cancer patients with bone metastasis. , 2015, The oncologist.

[13]  R. Coleman Clinical Features of Metastatic Bone Disease and Risk of Skeletal Morbidity , 2006, Clinical Cancer Research.

[14]  H. Sørensen,et al.  Survival in breast cancer patients with bone metastases and skeletal-related events: a population-based cohort study in Denmark (1999–2007) , 2011, Breast Cancer Research and Treatment.

[15]  D O Hancock,et al.  The value of postural reduction in the initial management of closed injuries of the spine with paraplegia and tetraplegia , 1969, Paraplegia.

[16]  R. Coleman Skeletal complications of malignancy , 1997, Cancer.

[17]  R. Cook,et al.  Methodology for treatment evaluation in patients with cancer metastatic to bone. , 2001, Journal of the National Cancer Institute.

[18]  K. Rankin,et al.  Metastatic Disease in Long Bones. A Proposed Scoring System for Diagnosing Impending Pathologic Fractures , 2014 .

[19]  K. Weinfurt,et al.  The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  R. Coleman Metastatic bone disease: clinical features, pathophysiology and treatment strategies. , 2001, Cancer treatment reviews.

[21]  G. Hortobagyi,et al.  Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases , 2000, Cancer.

[22]  C. Vogel,et al.  Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy. , 2004, The oncologist.

[23]  Lucila Ohno-Machado,et al.  Logistic regression and artificial neural network classification models: a methodology review , 2002, J. Biomed. Informatics.

[24]  C. Langer,et al.  The changing landscape of the medical management of skeletal metastases in nonsmall cell lung cancer , 2008, Current opinion in oncology.

[25]  J. Eastham,et al.  Rationale for zoledronic acid therapy in men with hormone-sensitive prostate cancer with or without bone metastasis. , 2006, Urologic oncology.

[26]  R. Coleman Bisphosphonates: clinical experience. , 2004, The oncologist.

[27]  M. Krzakowski,et al.  Long‐term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors , 2004, Cancer.

[28]  K. Weinfurt,et al.  Health-Related Quality of Life Among Patients With Breast Cancer Receiving Zoledronic Acid or Pamidronate Disodium for Metastatic Bone Lesions , 2004, Medical care.

[29]  X. Badia,et al.  Impact of skeletal complications on patients’ quality of life, mobility, and functional independence , 2008, Supportive Care in Cancer.